Rachaell Davis

Rachaell Davis is a journalist who has written for Essence, a monthly magazine for African American women. She has covered a variety of topics, including health and wellness, and has shown a particular interest in issues related to cancer research and treatment.

96%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

90%

Examples:

  • In the article 'Merck Oncology Is Working To Change The Narrative Around Triple Negative Breast Cancer', there is a noticeable bias favoring Merck Oncology's efforts in addressing Triple Negative Breast Cancer.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Merck's Efforts in Addressing Triple-Negative Breast Cancer and Racial Disparities

Broke On: Tuesday, 15 February 2022 Triple-negative breast cancer (TNBC) is a particularly aggressive form of the disease that disproportionately affects Black women. Black women are nearly twice as likely to be diagnosed with TNBC compared to their white counterparts. Racial disparities persist in breast cancer mortality rates, with Black women having a 40% higher breast cancer death rate compared to white women. Merck is developing innovative therapies and promoting health equity to address TNBC and the racial disparities in breast cancer mortality rates.